How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,143 results for

Life-Threatening Drug-Induced Rashes

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype. (PubMed)

of Medicine, University of Dundee, Dundee, U.K. Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, U.K. Institute of Medical Biology, Singapore. van Well G T J GT Department of Pediatrics, Maastricht University Medical Center, Maastricht, the Netherlands. Blokx W A M WA Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands. Schalkwijk J J Department of Dermatology, Radboud University Medical Center, Nijmegen (...) Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype. 27203668 2017 10 10 2017 10 10 1365-2133 176 1 2017 Jan The British journal of dermatology Br. J. Dermatol. Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype. 244-248 10.1111/bjd.14757 Volker-Touw C M L CM Department of Medical Genetics, University Medical

Full Text available with Trip Pro

2016 British Journal of Dermatology

22. Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review. (PubMed)

Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review. Cancer patients treated with epidermal growth factor receptor inhibitors (EGFRIs) frequently experience skin toxicities (rash) that can compromise their quality of life and lead to dose reduction or discontinuation of treatment. Reflecting the need for effective management of EGFRI-associated rash, a number of clinical practice guidelines and management recommendations have been developed (...) . The objective of this systematic review is to identify and summarize all available published recommendations of rash management strategies and evaluate their basis of evidence, to describe consensus in the recommendations, and where there is a lack of consensus to describe the opportunities for future clinical research to improve clinical practice in the management of EGFRI rash. Fifty-nine articles published from 2005-2011 were selected for inclusion in the systematic review. Common drug recommendations

2016 The Journal of community and supportive oncology

23. The strange connection between EGFR-TKIs and Dapsone: from the rash mitigation to the increase of anti-tumour activity. (PubMed)

The strange connection between EGFR-TKIs and Dapsone: from the rash mitigation to the increase of anti-tumour activity. The presence of an aberrantly activated epidermal growth factor receptor (EGFR) in many epithelial tumors, due to its overexpression, activating mutations, gene amplification and/or overexpression of receptor ligands, represent the fundamental basis underlying the use of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Drugs inhibiting the EGFR have different mechanisms of action (...) several interleukin-8 system inhibiting actions. Erlotinib typically gives a rash that has recently been proven to come out via up-regulated keratinocyte interleukin-8 synthesis with histological features reminiscent of typical neutrophilic dermatoses. In this review, we report experimental evidence that shows the use of dapsone to improve quality of life in erlotinib-treated patients by ameliorating rash as well as short-circuiting a growth-enhancing aspect of erlotinib based on increased interleukin

2016 Current medical research and opinion

24. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

.) Note: Table adapted from Table 7 in Endocrine and Metabolic Disorders: Diabetes Mellitus Chapter of Therapeutic Choices. © Canadian Pharmacists Association, 2016. All rights reserved. Source: . Accessed: November 30, 2016. Other information sources include the Government of Canada Notice of Compliance Database 29 and the Government of Canada Drug and Health Product Register. 34 Patient Group Insulin is a life-saving drug for T1D patients. 10 However, some T1D patients have difficulty obtaining (...) Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary There are two major

2018 CADTH - Issues in Emerging Health Technologies

25. Drug Reaction With Eosinophilia and Systemic Symptoms Induced by Valproic Acid: A Case Report (PubMed)

Drug Reaction With Eosinophilia and Systemic Symptoms Induced by Valproic Acid: A Case Report Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but life-threatening reaction to drugs such as carbamazepine and allopurinol. The condition is characterized by skin rashes, fever, hematological disturbances, lymphadenopathy, and organ failure, most probably hepatic dysfunction. To date, only a few cases of valproate-induced DRESS syndrome have been reported.We report (...) was initiated. Administration of the culprit drug to the patient was also stopped. Intravenous immunoglobulin (IVIG) improved the general condition of the patient.Only a small number of case reports have described valproic acid-induced DRESS syndrome; therefore, the condition is difficult to prevent. Rechallenge with valproic acid should be avoided in patients with a history of reaction to the drug.

Full Text available with Trip Pro

2016 Iranian Red Crescent medical journal

26. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug events induces systemic reactions in HIV-infected persons. (PubMed)

Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug events induces systemic reactions in HIV-infected persons. The incidence of cutaneous adverse drug reactions (CADRs) to first-line antituberculosis drugs (FLTDs) is higher in HIV-tuberculosis coinfection. However, the utility of patch testing to identify the offending drug in this patient subgroup has been poorly studied.To identify drugs causing adverse drug reactions in patients with HIV-tuberculosis (...) coinfection.Fourteen consecutive patients underwent diagnostic work-up (patch testing followed by a skin prick test and an oral rechallenge) to pinpoint the offending drug after developing FLTD-associated CADR, which included drug rash with eosinophilia and systemic symptoms (n = 12), Stevens-Johnson syndrome (SJS, n = 1) and toxic epidermal necrolysis/SJS overlap (n = 1). A positive reaction to any of the three diagnostic modalities eliminated that drug from the regimen. Once patients were clinically stable

2016 British Journal of Dermatology

27. Drug-induced Lupus

titer in Drug Induced Lupus: 95% in Drug Induced Lupus: >90% V. Prognosis Symptoms often recede with stopping causative agent Rarely life threatening VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Drug-induced Lupus." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Drug-induced lupus erythematosus (C0263591) Definition (NCI (...) -induced Lupus , Drug Induced Lupus , Systemic Lupus Secondary to Medication , Medication Causes of Systemic Lupus Erythematosus II. Causes More than 80 drugs associated (first described in 1945 related to sulfadiazine) (most common cause) ( ) Ethosuximide s s III. Symptoms (following causative medication use) See s Rash Serositis Hematologic abnormalities IV. Labs Screening indicated for causative medication use and symptoms suggestive of SLE (see above) ANA Titer Confirmatory testing if positive ANA

2018 FP Notebook

28. Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions

Status : Completed First Posted : July 31, 2017 Last Update Posted : August 8, 2017 Sponsor: SK Life Science, Inc. Information provided by (Responsible Party): SK Life Science, Inc. Study Details Study Description Go to Brief Summary: This study is aimed to investigate the influence of cenobamate on the activity of CYP3A4/5, CYP2B6, CYP2C19, and CYP2C9 by using drugs recommended by both the FDA and EMA as in vivo probes. In order to avoid a potential pharmacokinetic interaction between the probes (...) : Females who are breastfeeding Inadequate venous access History of any drug related hypersensitivity reactions as well as severe hypersensitivity reactions (like angioedema), or DRESS syndrome to any drugs in the opinion of the Investigator History of 1st degree relative having a serious cutaneous adverse reaction Current clinically significant rash Clinically significant history or evidence of gastrointestinal, hepatic, renal, endocrine, pulmonary, neurological, psychiatric, cardiovascular

2017 Clinical Trials

29. Emerging Drugs for Duchenne Muscular Dystrophy

Emerging Drugs for Duchenne Muscular Dystrophy Emerging Drugs for Duchenne Muscular Dystrophy | CADTH.ca CADTH Document Viewer Emerging Drugs for Duchenne Muscular Dystrophy Table of Contents Search this document Emerging Drugs for Duchenne Muscular Dystrophy June 2017 Summary Duchenne muscular dystrophy (DMD) is a rare and severe disorder that affects primarily young boys. It begins with progressive muscle weakness that evolves to loss of ambulation and further progresses to early morbidity (...) and mortality. DMD is caused by a mutation of the dystrophin gene that results in a lack of dystrophin, a protein that is necessary for muscle cell function. The mainstays of current therapy to treat DMD are corticosteroids and assistive devices. This bulletin focuses on new and emerging drugs for DMD with completed phase IIb or phase III trials and includes ataluren (nonsense mutation suppression), eteplirsen (exon 51 skipping), and idebenone (adenosine triphosphate [ATP] modulation). Ezutromid (utrophin

2017 CADTH - Issues in Emerging Health Technologies

30. Emerging Drugs for Duchenne Muscular Dystrophy

Emerging Drugs for Duchenne Muscular Dystrophy Emerging Drugs for Duchenne Muscular Dystrophy | CADTH.ca CADTH Document Viewer Emerging Drugs for Duchenne Muscular Dystrophy Table of Contents Search this document Emerging Drugs for Duchenne Muscular Dystrophy June 2017 Summary Duchenne muscular dystrophy (DMD) is a rare and severe disorder that affects primarily young boys. It begins with progressive muscle weakness that evolves to loss of ambulation and further progresses to early morbidity (...) and mortality. DMD is caused by a mutation of the dystrophin gene that results in a lack of dystrophin, a protein that is necessary for muscle cell function. The mainstays of current therapy to treat DMD are corticosteroids and assistive devices. This bulletin focuses on new and emerging drugs for DMD with completed phase IIb or phase III trials and includes ataluren (nonsense mutation suppression), eteplirsen (exon 51 skipping), and idebenone (adenosine triphosphate [ATP] modulation). Ezutromid (utrophin

2017 CADTH - Issues in Emerging Health Technologies

31. Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines

acuity (Snellen test) and color discrimination tests, followed by monthly inquiry about visual disturbance and monthly color dis- crimination tests. 7 Liver function tests only at baseline unless there were abnormal- ities at baseline, symptoms consistent with hepatotoxicity develop, or for patients who chronically consume alcohol, take other potentially hepatotoxic medications, or have viral hepatitis or history of liver disease, human immunodeficiency virus (HIV) infection, or prior drug-induced (...) concentration of ?rst-line drugs than administration with food [54]. Any combination of otherwise unexplained nausea, vomiting, and abdominal painisevaluatedwithaphysicalexaminationandliverfunction tests, including alanine aminotransferase (ALT), aspartate ami- notransferase (AST), bilirubin, and alkaline phosphatase to as- sess for possible hepatotoxicity [55].Drug-induced hepatitis is the most frequent serious adverse reaction to the ?rst-line drugs. INH, RIF, and PZA can cause drug-induced liver injury

2016 American Thoracic Society

32. A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. (PubMed)

A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Agents targeting the epidermal growth factor receptor (EGFR) are amongst the most extensively used of the targeted agents in the therapy of some of the most common solid tumors. Although they avoid many of the classic side effects associated with cytotoxic chemotherapy, they are associated with unpleasant cutaneous toxicities which can affect (...) treatment compliance and impinge on patient quality of life. To date, despite a plethora of consensus recommendations, expert opinions and reviews, there is a paucity of evidence-based guidance for the management of the skin rash that occurs in the treatment of patients receiving EGFR-targeted therapies.A literature search was conducted as a first step towards investigating not only an evidence-based approach to the management of skin rash, but also with a view to designing future randomized trials.The

Full Text available with Trip Pro

2013 Radiology and oncology

33. Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage (PubMed)

Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage Cutaneous adverse reactions (CARs) from antiepileptic drugs (AEDs) are common, ranging from mild to life-threatening, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The identification of subjects carrying the HLA-B*15:02, an inherited allelic variant of the HLA-B gene (...) , and the avoidance of carbamazepine (CBZ) therapy in these subjects are strongly associated with a decrease in the incidence of carbamazepine-induced SJS/TEN. In spite of the strong genetic associations, the initiation of hypersensitivity for AEDs is still not very well characterized. Predicting the potential for other AEDs to cause adverse reactions will be undoubtedly beneficial to avoid CARs, which is the focus of this report. Here, we explore the use of the Biopharmaceutics Drug Disposition Classification

Full Text available with Trip Pro

2016 The AAPS journal

34. Human leukocyte antigens: key regulators of T-cell mediated drug hypersensitivity (PubMed)

by T cells are associated with phenotypically distinct clinical diagnoses and can vary from a mild delayed rash to a life-threatening cutaneous, systemic or organ disease, such as Stephen Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms and drug-induced liver disease. T-cell-mediated ADRs are strongly linked to the carriage of particular HLA risk alleles which are in the case of abacavir hypersensitivity and HLA-B*57:01 has led to translation (...) Human leukocyte antigens: key regulators of T-cell mediated drug hypersensitivity Adverse drug reactions (ADR) can be broadly categorised as either on-target or off-target. On-target ADRs arise as a direct consequence of the pharmacological properties of the drug and are therefore predictable and dose-dependent. On-target ADRs comprise the majority (>80%) of ADRs, relate to the drug's interaction with its known pharmacological target and are a result of a complex interplay of genetic

Full Text available with Trip Pro

2018 HLA

35. Antiretroviral / HIV Drug Dosing for Paediatrics

function, blood and urine monitoring. TD + FTC Truvada ® (Gilead) Child: Not recommended 35kg)? 1 tab OD Tab: TD 245mg/FTC 200mg (blue) Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Do TDM for both NNRTs and PIs in combination. Do TDM with Rifamycins. Long half-life consider cover with PI after stopping Nevirapine (NVP) Viramune ® Viramune-XR ® (Boehringer) Child lead in period: 150-200mg/m 2 OD for 14 days (max 200mg/day), then if no rash or LFT abnormalities increase to 150-200mg/m 2 BD (...) ) Atazanavir (ATV) Reyataz ® (BMS) Child: (>6years) (15- 40kg)? 300mg OD + RTV 100mg OD Adult: 300mg OD with RTV 100mg OD Caps: 150mg (dark blue/light blue), 200mg (dark blue), 300mg (dark blue/red) Capsules can be opened and contents mixed with water/apple sauce PPIs contraindicated (?ATV exposure). Take with food. If dyspepsia, use Gaviscon or ranitidine 12- hours apart from dose. Nausea, headaches, rash, jaundice Ritonavir (RTV) Norvir ® (Abbott) Child: For boosting other PIs see specific drug

2015 The Children's HIV Association

36. Drugs to avoid in 2015

, arrhyth- mias) due to their noradrenergic activi- ty. Venlafaxine also causes QT prolongation (Rev Prescrire n° 338; 343; 362, 374). – Tianeptine, a drug with no proven effi- cacy, can cause hepatitis, life-threatening skin reactions (including bullous rash), abuse and addiction (Prescrire Int n° 127 and 132). Other psychotropic drugs. Some other psychotropic drugs have unac- ceptable adverse effects: – Asenapine, a drug somewhat less effec- tive than other neuroleptics in manic episodes associated (...) probenecid, is inade- quate or risky, it is more prudent to manage attacks with symptomatic treat- ments, pending a better solution. – Quinine, used to treat cramps, can have life-threatening adverse effects including anaphylactic reactions, haematological disorders (including thrombocytopenia, haemolytic anaemia, agranulocytosis, and pancytopenia) and cardiac arrhyth- mias. These adverse effects are dispro- portionate in view of its poor efficacy (Rev Prescrire n° 337; 344). There are no drugs

2015 Prescrire

37. Closed-System Transfer Devices for the Handling of Hazardous Drugs

not be possible and there is still a risk of exposure for staff regularly handling hazardous drugs due to user technique or unpredictable spills. 2 Occupational exposure may be measured by biological monitoring of staff using urine samples or cytogenic testing, or environmental monitoring of the workplace using wipe and air sampling of marker drugs. 1,2 Although the clinical significance of long-term, low-level exposure to chemotherapy drugs is not fully known, potential hazards include rash, infertility (...) Closed-System Transfer Devices for the Handling of Hazardous Drugs Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

38. Nappy rash

. Skin trauma — for example, mechanical friction from skin contact with nappies or over-vigorous cleaning. Medication — recent broad-spectrum antibiotics, in particular, predispose to candida colonization; other drugs that increase stool frequency may also increase the risk. Gestational age — pre-term infants are at increased risk of developing nappy rash and secondary infection due to the reduced barrier function of immature skin. Diarrhoea — including conditions associated with increased stool (...) effects Adverse effects Topical imidazoles are generally well tolerated. Possible adverse effects include: Local skin irritation, rash, erythema, itch, mild burning sensation, and hypersensitivity reactions. Treatment should be discontinued if these are severe. [ ] Drug interactions Drug interactions Possible drug interactions with topical imidazoles include: Oral miconazole and econazole are known to inhibit CYP450 enzymes, but due to the limited systemic availability of topical preparations

2013 NICE Clinical Knowledge Summaries

39. Skin rash in the intensive care unit: Stevens-Johnson syndrome, toxic epidermal necrolysis, or a rare manifestation of a hidden cutaneous malignancy: A case report (PubMed)

Skin rash in the intensive care unit: Stevens-Johnson syndrome, toxic epidermal necrolysis, or a rare manifestation of a hidden cutaneous malignancy: A case report Skin rashes are infrequently encountered in the intensive care units, either as a result or as a cause of admission. The entities of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) form a spectrum of desquamating skin diseases that have multiple etiologies, the most common being drug-related reactions; very rarely (...) of skin biopsy when encountering SJS and TEN in the ICU in order to identify potentially treatable/controllable causes. Although it appeared reasonable to correlate TEN solely to medications, the skin biopsies clearly demonstrated an aggressive T-cell skin lymphoma. In a patient with a better general condition it may have been helpful to treat this malignancy. TEN is a life-threatening condition and skin biopsy is the cornerstone of diagnosis, despite the presence of multiple risk factors

Full Text available with Trip Pro

2015 Molecular and clinical oncology

40. Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01299220 Recruitment Status : Withdrawn (Unable to enroll subjects by sponsor deadline) First Posted : February 18, 2011 Last Update Posted : January 16, 2013 Sponsor

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>